A61K 38/46
Hydrolases
Official title: Hydrolases (3)
A61K38/46 (Hydrolases) appears on 6,054 US grants and 11,268 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,054
- Published applications
- 11,268
- Assignees
- 3,304
- Inventors
- 14,626
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 7 | 0 |
| 1978 | 3 | 0 |
| 1979 | 5 | 0 |
| 1980 | 3 | 0 |
| 1981 | 8 | 0 |
| 1982 | 4 | 0 |
| 1983 | 3 | 0 |
| 1984 | 14 | 0 |
| 1985 | 12 | 0 |
| 1986 | 7 | 0 |
| 1987 | 10 | 0 |
| 1988 | 10 | 0 |
| 1989 | 14 | 0 |
| 1990 | 19 | 0 |
| 1991 | 24 | 0 |
| 1992 | 24 | 0 |
| 1993 | 24 | 0 |
| 1994 | 27 | 0 |
| 1995 | 31 | 0 |
| 1996 | 36 | 0 |
| 1997 | 44 | 0 |
| 1998 | 64 | 0 |
| 1999 | 71 | 0 |
| 2000 | 74 | 0 |
| 2001 | 83 | 42 |
| 2002 | 106 | 194 |
| 2003 | 82 | 227 |
| 2004 | 61 | 259 |
| 2005 | 85 | 276 |
| 2006 | 87 | 274 |
| 2007 | 79 | 284 |
| 2008 | 92 | 317 |
| 2009 | 76 | 291 |
| 2010 | 138 | 376 |
| 2011 | 137 | 374 |
| 2012 | 193 | 382 |
| 2013 | 233 | 453 |
| 2014 | 300 | 531 |
| 2015 | 312 | 564 |
| 2016 | 315 | 606 |
| 2017 | 349 | 568 |
| 2018 | 344 | 552 |
| 2019 | 360 | 653 |
| 2020 | 368 | 607 |
| 2021 | 355 | 658 |
| 2022 | 313 | 665 |
| 2023 | 269 | 603 |
| 2024 | 319 | 593 |
| 2025 | 270 | 522 |
| 2026 | 186 | 397 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Protease composition6 Oct 2026US 12,751,997 B2Anatara Lifesciences Limited
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Methods of treating ischemic disease by administering an ATR kinase inhibitor22 Sep 2026US 12,740,980 B2East Tennessee State University Research Foundation
- Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma22 Sep 2026US 12,742,018 B2Janssen Biotech, Inc.
- Cosmetic composition comprising an endolysin and an organic filler8 Oct 2026US 2026/0306385 A1L'oreal
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Plasmin-induced internal limiting membrane digestion facilitates donor retinal ganglion cell transplantation8 Oct 2026US 2026/0306549 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Treating muscle weakness with alkaline phosphatases8 Oct 2026US 2026/0306590 A1
Most cited
By later US patents
- Non-immunogenic polypeptides2,007US 4,179,337 A1979
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014
- Drug delivery system making use of a hydrogel polymer coating1,007US 5,304,121 ABoston Scientific Corporation · 1994
- Biodegradable botulinum toxin implant657US 6,506,399 B2Allergan Sales, Inc. · 2003
- CRISPR-Cas systems and methods for altering expression of gene products483US 8,945,839 B2Massachusetts Institute of Technology · 2015